ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03547700` - Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)	Phase 1/Phase 2
Completed	`NCT02788916` - A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas	N/A
Completed	`NCT02567656` - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma	Phase 1
Completed	`NCT01142674` - T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
Withdrawn	`NCT03355768` - Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL	Phase 3
Not yet recruiting	`NCT05006664` - Brentuximab Vedotin in Combination With CHEP in Patient With PTCL	Phase 2
Terminated	`NCT00514722` - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies	N/A
Completed	`NCT01679860` - Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma	Phase 2
Recruiting	`NCT06254495` - A Safety Study of SGN-35C in Adults With Advanced Cancers	Phase 1
Completed	`NCT05137847` - A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Terminated	`NCT03601819` - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Phase 1
Completed	`NCT03049449` - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Phase 1
Completed	`NCT00211185` - A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT03051581` - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma	N/A
Not yet recruiting	`NCT03051568` - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma	N/A
Completed	`NCT00646854` - Alemtuzumab and CHOP in T-cell Lymphoma	Phase 3
Terminated	`NCT02535247` - Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT02364466` - Cohort of Peripheral T Cell Lymphoma	N/A
Recruiting	`NCT02404571` - GDP in Frontline Chemotherapy for Patients With PTCL-NOS	Phase 2
Completed	`NCT02181218` - Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas	Phase 1

NCT number	NCT03742921
Study type	Observational
Source	Celgene
Contact
Status	Completed
Phase
Start date	February 4, 2019
Completion date	October 31, 2023

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms